Is 99mTc-labelled pamidronate a better agent than 99mTc-medronate for bone imaging?

Nuclear Medicine Communications

Volumn 28, Issue 2, 2007, Pages 101-107

  Kumar, Vijay ^a,b   Kumar, Divesh ^a,b   Howman Giles, Robert B ^a,b   Little, David G ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b University of Sydney   (Australia)

Author keywords

Biodistribution; Bone fracture; Bone uptake; Renal excretion

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DIAGNOSTIC AGENT; MEDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 3 AMINO 1 HYDROXYPROPANE 1,1 DIPHOSPHONATE; TECHNETIUM TC 99M 3-AMINO-1-HYDROXYPROPANE-1,1-DIPHOSPHONATE; UNCLASSIFIED DRUG; PAMIDRONIC ACID TC 99M; PERTECHNETIC ACID TC 99M;

ANIMAL; ARTICLE; BONE; FEMUR; FRACTURE; INSTRUMENTATION; MALE; METHODOLOGY; PATHOLOGY; RAT; SCINTISCANNING; TIME; WISTAR RAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD; BONE SCINTISCANNING; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG LABELING; DRUG POTENCY; DRUG RETENTION; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMUR FRACTURE; FUNCTIONAL ASSESSMENT; ISOTOPE LABELING; KIDNEY; LIVER; NONHUMAN; ORGAN DISTRIBUTION; REDUCTION KINETICS; SOFT TISSUE; STATISTICAL SIGNIFICANCE; TISSUE DISTRIBUTION; URINARY EXCRETION;

ANIMALS; BONE AND BONES; DIPHOSPHONATES; FEMUR; FRACTURES, BONE; MALE; ORGANOTECHNETIUM COMPOUNDS; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; TECHNETIUM TC 99M MEDRONATE; TIME FACTORS;

EID: 33845968496     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328013eb74     Document Type: Article

References (26)

1. Shaw NJ, Bishop NJ. Bisphosphonate treatment of bone disease. Arch Dis Child 2005; 90:494-499.
2. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonnen J, Frith JC, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88:2961-2978.
3. 99mTc-MDP. Nucl Med Biol 1997; 24:27-33.
4. Clanton JA. Radiopharmacokinetics in nuclear medicine. In: Hladik WB, Saha GB, Study KT (editors): Essentials of Nuclear Medicine Science. Baltimore: William & Wilkins; 1987, pp. 20-33.
5. Hosain P, Wang TST. Bone imaging compounds with special reference to structure-affinity relationship. In: Spencer RP (editor): Radiopharmaceutical Structure-Affinity Relationships. New York: Grune & Stratton; 1981, pp. 531-537.
6. Subramanian G, McAfee JG, Blair RJ, Kallfelz FA, Thomas FD. Technetium-99m-methylene diphosphonate - a superior agent for skeletal imaging: comparison with other technetium complexes. J Nucl Med 1975; 16:744-755.
7. 99mTc-EHDP: a potential radiopharmaceutical for skeletal imaging. J Nucl Med 1972; 13:947-950.
8. Fogelman I, Citrin DL, McKillop JH, Turner JG, Bessent RG, Greig WR. A clinical comparison of Tc-99m HEDP and Tc-99m MDP in the detection of bone metastases: concise communication. J Nucl Med 1979; 20:98-101.
9. Murray IPC, McKay WJ, Robson J, Sorby P, Boyd RE. Skeltec, a thermo-stable Tc-99m agent for skeletal scintigraphy. J Nucl Med 1972; 13:445.
10. Degrossi OJ, Oliveri P, Garcia del Rio H, Labriola R, Artagaveytia D, Degrossi EB. Technetium-99m APD compared with technetium-99m MDP as a bone scanning agent. J Nucl Med 1985; 26:1135-1139.
11. 99mTc-labelled APD in the mouse. Calcif Tissue Int 1988; 43:125-127.
12. Buell U, Kleinhans E, Zorn-Bopp E, Reuschel W, Muenzing W, Moser EA, Seiderer M. A comparison of bone imaging with Tc-99m DPD and Tc-99m MDP: concise communication. J Nucl Med 1982; 23:214-217.
13. Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Delivery 2000; 42:175-195.
14. Fleisch H. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med 1997; 29:55-62.
15. Russell RG, Rogers MJ. Bisphosphonates: from laboratory to the clinic and back again. Bone 1999; 25:97-100.
16. Uludag H. Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des 2002; 21:1929-1944.
17. Little DG, Cornell MS, Cowell CT, Briody J, Arbuckle S, Cooke-Yarborough C. Intravenous pamidronate reduces osteoporosis and improves regenerate formation during distraction osteogenesis in immature rabbits. J Bone Joint Surg 2001; 7:1069-1074.
18. Little DG, Smith NC, Williams PR, Briody JN, Bilston LE, Smith EJ, et al. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res 2003; 7:1300-1307.
19. Rudd TG, Allen DR, Smith FD. Technetium-99m-labeled methylene diphosphonate and hydroxyethylidine diphosphonate - biologic and clinical comparison: concise communication. J Nucl Med 1979; 20:821-826.
20. Fogelman I, Pearson DW, Bessent RG, Tofe AJ, Francis MD. A comparison of skeletal uptakes of three diphosphonates by whole-body retention: concise communication. J Nucl Med 1981; 22:880-883.
21. 99mTc-labeled 1-hydroxy-ethylidene-1,1-disodium phosphonate. J Nucl Med 1972; 13:823-827.
22. Yano Y, McRae J, Van Dyke DC, Anger HO. Technetium-99m-labeled stannous ethane-1-hydroxy-1 1-diphosphonate: a new bone scanning agent. J Nucl Med 1973; 14:73-78.
23. Pauwels EKJ, Blom J, Camps JAJ, Hermans J, Rijke AM. A comparison between the diagnostic efficacy of Tc-99m-MDP, Tc-99m-DPD and Tc-99m-HDP for the detection of bone metastases. Eur J Nucl Med 1983; 8:118-122.
24. Subramanian G, McAfee JG, Thomas FD, Feld TA, Zapf-Longo C, Palladino E. New diphosphonate compounds for skeletal imaging: comparison with methylene diphosphonate. Radiology 1983; 149:823-828.
25. Delaloye B, Delaloye-Bischof A, Dudczak R, Koppenhagen K, Mata F, Penafiel A, et al. Clinical comparison of Tc-99m-HMDP and Tc-99m-MDP. Eur J Nucl Med 1985; 11:182-185.
26. 14C]Clodronate (dichloromethylene bisphosphonate) disodium in mice. Toxicol Appl Pharmacol 1987; 89:287-292.